Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYCR1 | P32322 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 3/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL607790 | 0.98 | PYCR1 (0.46) | PYCR1CYP2A6CCR5ALDH1A1SIGMAR1 | |
| SCHEMBL20425681 | 0.83 | TAAR1 (0.52) | PYCR1HTR2ATRPM8TAAR1 | |
| SCHEMBL29890016 | 0.83 | TAAR1 (0.52) | PYCR1HTR2ATRPM8TAAR1 | |
| SCHEMBL2550855 | 0.82 | CYP2A6 (0.44) | PYCR1CYP2A6CCR5ALDH1A1MAPK1 | |
| SCHEMBL31142940 | 0.82 | CYP2A6 (0.44) | PYCR1CYP2A6CCR5ALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL7637186 | 0.81 | TAAR1 (0.50) | PYCR1MAPK1HTR2ATRPM8TAAR1 | |
| Hydrochloric Acid SCHEMBL29507155 | 0.81 | TAAR1 (0.50) | PYCR1MAPK1HTR2ATRPM8TAAR1 | |
| SCHEMBL8587109 | 0.80 | PYCR1 (0.46) | PYCR1ALDH1A1SIGMAR1MAPK1CA1 | |
| SCHEMBL12164465 | 0.79 | PYCR1 (0.49) | PYCR1ALDH1A1MAPK1CA1CA2 | |
| SCHEMBL307129 | 0.79 | PYCR1 (0.49) | PYCR1ALDH1A1SIGMAR1MAPK1CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2012-02-16 | — | — | US | claimed |
| EP-1981831-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | Vaidya, Niteen A. (US) | 2008-10-22 | — | — | EP | claimed |
| WO-2007092264-A2 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | VAIDYA NITEEN A (US) | 2007-08-16 | — | — | WO | claimed |
| US-20070185346-A1 | Kit for automated resolving agent selection and method thereof | VAIDYA NITEEN A | 2007-08-09 | — | — | US | claimed |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | VANDERBILT UNIV (US) | 2026-05-21 | — | — | US | disclosed |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BIOGEN MA INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | MERCK SHARP & DOHME LLC (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250282760-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2025-09-11 | — | — | US | disclosed |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| CN-120081791-A | Heteroaryl compounds, process for their preparation and their use in medicine | 江苏恒瑞医药股份有限公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4518853-A1 | OREXIN RECEPTOR AGONISTS | Merck Sharp & Dohme LLC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | BIOGEN MA INC. (US) | 2025-03-04 | — | — | US | disclosed |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | GILEAD SCIENCES. INC. | 2005-10-27 | — | — | US | disclosed |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | GILEAD SCIENCES, INC. | 2005-09-22 | — | — | US | disclosed |
| CN-1649885-A | Cellular Accumulation of Phosphonate Analogs of HIV Protease Inhibitor Compounds and Such Compounds | GILEAD SCIENCES INC (US) | 2005-08-03 | — | — | CN | disclosed |
| WO-2005064008-A1 | METHOD AND COMPOSITIONS FOR IDENTIFYING ANTI-HIV THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| EP-1509537-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2005-03-02 | — | — | EP | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| US-5034537-A | Alpha-methyl-4-halobenzenemethanamine salts of acids for cardiovascular disorders, respiratory system disorders and antiallergens | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240838-B2 | Inhibiting agents for Bruton's tyrosine kinase | ABL1, BTK, LYN | PYCR1 3474/4885CYP2A6 3708/4885CCR5 3491/4885 |
| US-12570631-B2 | Substituted N-(4-(pyrimidin and pyridin-4-yl)benzylcarboxamides and its use for treating disorders responsive to inhibition of Btk | BTK, LYN, SYK | PYCR1 2529/4885CYP2A6 1158/4885CCR5 825/4885 |
| US-20120041225-A1 | KIT FOR AUTOMATED RESOLVING AGENT SELECTION AND METHOD THEREOF | ACKR3, KIT, C3AR1 | PYCR1 2448/4885CYP2A6 381/4885CCR5 60/4885 |
| US-20050209197-A1 | Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds | PPA1, PPME1, PNP | PYCR1 2621/4885CYP2A6 3590/4885CCR5 2161/4885 |
| US-20050239054-A1 | Method and compositions for identifying anti-HIV therapeutic compounds | CES1, PNP, PGLS | PYCR1 2164/4885CYP2A6 811/4885CCR5 1489/4885 |
| US-20250282760-A1 | OREXIN RECEPTOR AGONISTS | HCRTR2, HCRTR1, OXTR | PYCR1 527/4885CYP2A6 1291/4885CCR5 548/4885 |
| US-20260138978-A1 | POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1 | CHRM1, CHRM4, CHRM2 | PYCR1 2221/4885CYP2A6 1827/4885CCR5 280/4885 |
| US-12454525-B2 | IL4I1 inhibitors and methods of use | IL4I1, IL4, IL2 | PYCR1 3767/4885CYP2A6 1833/4885CCR5 555/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | PYCR1 2399/4885CYP2A6 4317/4885CCR5 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.